PL Detail-Document #301105
−This Detail-Document accompanies the related article published in−
PHARMACIST’S LETTER / PRESCRIBER’S LETTER
November 2014
Magic Mouthwash Recipes
Ingredients1-11,a-e
Amount
Diphenhydramine 12.5 mg/5 mL 240 mL
Hydrocortisone
60 mg
Nystatin powder
6 million
units
Tetracycline
1.5 g
Swish and spit 5 mL QID.
a.k.a. Mary’s Magic Potion
Ingredients1-11,a-e
Hydrocortisone
Nystatin
Diphenhydramine 12.5 mg/5 mL
a.k.a. Duke’s Magic Mouthwash4
Amount
60 mg
Suspension
30 mL OR
Powder
3 million
units
QS 240 mL
Distilled water
160 mL
Hydrocortisone
80 mg
Maalox
80 mL
Swish and spit 5 mL QID.
a.k.a. Weisman’s Philadelphia Mouthwash
Diphenhydramine 12.5 mg/5 mL
Hydrocortisone
Nystatin suspension
Tetracycline
Diphenhydramine 12.5 mg/5 mL
Nystatin suspension
Maalox
Water
Diphenhydramine 12.5 mg/5 mL
Hydrocortisone
Nystatin suspension
Tetracycline
100 mL
0.02 g
4.8 mL
200 mg
Diphenhydramine 12.5 mg/5 mL
Prednisone 5 mg/5 mL
Nystatin suspension
1 part
1 part
1 part
Nystatin Susp. 100,000 U/mL
Lidocaine Viscous 2%
Distilled Water
Crystal Light-Raspberry with
Aspartame crystals8
83.3 mL
83.3 mL
83.3 mL
0.47 g
1 part
1 part
1 part
1 part
Diphenhydramine 12.5 mg/5 mL 1 part
Viscous lidocaine 2%
1 part
Maalox
1 part
Swish and swallow 5 mL no more than Q4H.
OR For radiation oncology mucositis; palliative
care:
Swish, hold, and spit or swallow 30 mL Q2H.1
Diphenhydramine 12.5 mg/5 mL
240 mL
Hydrocortisone powder
120 mg
(wet with 1% CMCf to dissolve)
Nystatin Suspension
60 mL
Tetracycline 125 mg/5 mL
120 mL
(capsule dissolved in flavored
syrup)
CMCf 1%
QS 480 mL
Swish and swallow 10 mL TID.
Diphenhydramine 12.5 mg/5 mL
Mylanta or Maalox
Sucralfate
Swish and spit or swallow 5 mL
meals and PRN.6
30 mL
60 mL
4g
TID before
180 mL
0.072 g
36 mL
0.75 g
Cherry-flavored Kool-Aid mixed
100 mL
with 2000 mL distilled water
(sugar-free)
Viscous lidocaine 2%
100 mL
Nystatin suspension
100 mL
Swish and spit or swallow 15 mL QID. OR
For radiation oncology mucositis; palliative
care:
Swish, hold, and spit or swallow 30 mL Q4H.1
a.k.a. Koolstat
More. . .
Copyright © 2014 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.PharmacistsLetter.com ~ www.PrescribersLetter.com ~ www.PharmacyTechniciansLetter.com
(PL Detail-Document #301105: Page 2 of 3)
Ingredients1-11,a-e
Amount
Hydrocortisone 100 mg/2 mL
12 mL
(Solu-Cortef)
Nystatin suspension
7.2 mL
Tetracycline 125 mg/5 mL
12 mL
(capsule dissolved in syrup)
Diphenhydramine 12.5 mg /5 mL 150 mL
Swish and swallow 10 mL QID.
Viscous lidocaine 2%
Hydrocortisone 100 mg/2 mL
(Solu-Cortef)
Nystatin suspension
Mouth rinse
Do not swallow.
250 mL
1g
150 mL
QS 500 mL
Diphenhydramine 12.5 mg /5 mL
Dexamethasone 4 mg/mL injection
Nystatin suspension
Distilled water QS to 200 mL8
Swish and Spit 5 mL QID.
120 mL
0.56 mL
40 mL
Viscous lidocaine 2%
Cherry flavored Kool-Aid mixed
with 1500 mL of sterile water for
irrigation (sugar-free)
2000 mL
QS
3400 mL
Diphenhydramine 12.5 mg/5 mL
Prednisone 5 mg/5 mL
Nystatin suspension
1 part
1 part
1 part
Viscous lidocaine 2%
80 mL
Mylanta
80 mL
Diphenhydramine 12.5 mg/5 mL
80 mL
Nystatin suspension
80 mL
Prednisolone 15 mg/5 mL
80 mL
Distilled water
80 mL
Swish, gargle, and spit 5 mL to 10 mL Q6H
PRN.
May be swallowed if esophageal
involvement.10
Viscous lidocaine 2%
150 mL
Diphenhydramine 12.5 mg/5 mL
20 mL
Hydrocortisone (Solu-Cortef)
100 mg
Tetracycline
2 grams
Nystatin suspension
20 mL
Swish, hold, and swallow 15 to 30 mL Q4-6H.1
a.k.a. Mile’s Solution
Ingredients1-11,a-e
Amount
Viscous lidocaine 2%
30 mL
Maalox
60 mL
Diphenhydramine 12.5 mg/5 mL
30 mL
Carafate 1 g/10 mL
40 mL
Swish, gargle, and spit 5 mL to 10 mL Q6H
PRN. May swallow if esophageal involvement.10
Dexamethasone 0.5 mg/5 mL
100 mL
Diphenhydramine 12.5 mg/5 mL
100 mL
Nystatin suspension
60 mL
Tetracycline
1500 mg
Swish, gargle, and spit 5 mL to 10 mL Q6H
PRN. May swallow if esophageal
involvement.10
a. Elixirs containing alcohol can cause stinging.
Consider using injectable or powder
formulation, crushing tablets, or opening
capsules in place of elixir formulation to
avoid stinging.
b. Some U.S. clinicians have found the new
formulation of Kaopectate (i.e., containing
bismuth) to solidify over a short period of
time when mixed with other ingredients. U.S.
clinicians should consider this potential
problem if utilizing recipes which use
Kaopectate in place of Maalox. Canadian
Kaopectate formulation does not contain
bismuth.
c. Nystatin has not been shown to be effective in
treating oral fungal infection associated with
oral mucositis.11
d. The use of corticosteroids, such as
hydrocortisone or dexamethasone, has not
been adequately studied to recommend its
inclusion in magic mouthwash.11
e. In general, per USP standards, oral mixtures
containing water should have an expiration
not longer than two weeks (refrigerated) and
mucosal mixtures containing water should
have an expiration of not longer than 30 days
(room temp).12
f. CMC=Carboxymethylcellulose.
Users of this PL Detail-Document are cautioned to use their
own professional judgment and consult any other necessary
or appropriate sources prior to making clinical judgments
based on the content of this document. Our editors have
researched the information with input from experts,
government agencies, and national organizations.
Information and internet links in this article were current as
of the date of publication..
More. . .
Copyright © 2014 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.PharmacistsLetter.com ~ www.PrescribersLetter.com ~ www.PharmacyTechniciansLetter.com
(PL Detail-Document #301105: Page 3 of 3)
Project Leaders in preparation of this PL DetailDocument: Wan-Chih Tom, Pharm.D. (Original
November 2009 version); Stacy A. Hester, R.Ph.,
BCPS, Assistant Editor (November 2014 update)
References
1.
2.
3.
4.
5.
The Erie St. Clair Palliative Care Management
Tool.
January
2007.
http://palliativecareswo.ca/PalliativeCareManagme
nTool_v3.2.pdf. (Accessed October 14, 2014).
Anon.
Slang terms and jargon can cause
medication errors. Drugs & Therapy Bulletin.
Shands
at
the
University
of
Florida.
November/December 2005. Volume 19, Number
10.
http://professionals.ufhealth.org/files/2011/11/1005drugs-therapy-bulletin.pdf. (Accessed October 14,
2014).
Bulletin Board of Oral Pathology. University at
Buffalo. 2007.
North
Carolina
Board
of
Pharmacy.
http://www.ncbop.org/faqs/Pharmacist/faq_DukesM
agicMouthwash.htm.
(Accessed October 14,
2014).
Hodgins C, Mosley M, Pola-Strowd M.
Recommendations
for the
diagnosis
and
management of recurrent aphthous stomatitis.
2003. University of Texas at Austin, School of
Nursing.
6.
Tarascon Pharmacopoeia. 2009 Library Edition.
Ed. In Chief: Richard J. Hamilton. Jones &
Bartlett. Sudbury, MA:164.
7. Department of Pharmacy Services. Mount Sinai
Hospital. Toronto, Ontario MSG 1XS. October
2009.
8. Toronto Sunnybrook Regional Cancer Centre
Pharmacy. Toronto, Ontario M4N 3M5. October
2009.
9. Drug Information and Research Centre. Ontario
Pharmacist’s Association. October 2009.
10. Randy Otterholt, DDS General Dentistry.
http://www.drotterholt.com/magicmouthwash.html.
(Accessed October 14, 2014).
11. Chan A, Ignoffo RJ.
Survey of topical oral
solutions for the treatment of chemo-induced oral
mucositis. J Oncol Pharm Pract 2005;11:139-43.
12. Chapter 795 Pharmaceutical Compounding-Nonsterile Preparations.
The United States
Pharmacopeia and The National Formulary (USPNF).
http://www.usp.org/sites/default/files/usp_pdf/EN/gc
795.pdf. (Accessed October 14, 2014).
Cite this document as follows:
PL Detail-Document, Magic Mouthwash Recipes.
Letter/Prescriber’s Letter. November 2014.
Pharmacist’s
Evidence and Recommendations You Can Trust…
3120 West March Lane, Stockton, CA 95219 ~ TEL (209) 472-2240 ~ FAX (209) 472-2249
Copyright  2014 by Therapeutic Research Center
Subscribers to the Letter can get PL Detail-Documents, like this one,
on any topic covered in any issue by going to www.PharmacistsLetter.com,
www.PrescribersLetter.com, or www.PharmacyTechniciansLetter.com
PL Detail-Document #301105
−This PL Detail-Document gives subscribers
additional insight related to the Recommendations published in−
PHARMACIST’S LETTER / PRESCRIBER’S LETTER
November 2014
Prevention and Treatment of Oral Mucositis
Oral mucositis is mucosal ulceration caused by chemotherapy or radiation treatment. Mucositis can affect not only the mouth, but also the
pharyngeal, laryngeal, and esophageal areas.1 Mucositis is usually very painful and can be slow to heal.1-3 It can reduce an individual’s ability to
tolerate cancer treatment, maintain nutritional intake (e.g., drink, eat, swallow), or speak.1,4 Treatment guidelines have been developed for prevention
and treatment of oral mucositis by the Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology
(ISOO) (http://www.mascc.org/assets/Guidelines-Tools/mascc%20isoo%20mucositis%20guidelines%20summary%201feb2014.pdf). The National
Cancer
Institute
(NCI)
also
provides
recommendations
(http://www.cancer.gov/cancertopics/pdq/supportivecare/oralcomplications
/HealthProfessional/page5) as does the National Comprehensive Cancer Network (NCCN, http://www.nccn.org/JNCCN/PDF/mucositis_2008.pdf).
Stomatitis is a term that is sometimes used interchangeably with mucositis, but is actually more general and describes any inflammatory condition of
oral tissue.2 Canker sores are also different from oral mucositis. Their cause is unclear but they tend to be recurrent and triggered by factors such as
smoking, stress, etc. For more info on treatment of canker sores, go to our PL Detail-Document, Treatment of Canker Sores. The following chart
lists commonly asked questions about the treatment of oral mucositis. Keep in mind that the effectiveness of interventions may depend on factors
such as treatments and the type of cancer being treated.
QUESTION
How can oral mucositis be
prevented?
ANSWER




What nondrug therapies
can be recommended for
patients with oral
mucositis?



Proper oral hygiene can help minimize severity of oral mucositis.1,2
Holding ice chips in the mouth, or cryotherapy, during treatment may help prevent mucositis in some
situations.1,3,12
Oral zinc supplements may be helpful in some patients.1
Rx palifermin (Kepivance) is FDA- and Health Canada-approved for prevention of oral mucositis in certain
oncology patients.1,2 It can reduce severity and duration of mucositis.5
Maintain proper oral hygiene, such as brushing the teeth with a soft-bristle toothbrush and flossing with gentle
irrigation using a water flosser on a low setting.1,5
Avoid irritating foods or beverages (e.g., dry, salty, acidic, hard, hot).5
Rinsing frequently, such as every four hours or between medicated mouth rinse doses, with a bland solution, such
as one teaspoon of table salt in 32 oz. (1 L) of water (to make 0.9% sodium chloride) with or without one to two
tablespoons of sodium bicarbonate, can be tried.1,2,5,12 This mixture can be used at room temperature or
refrigerated. The patient should rinse and swish then spit.2 (Note that experts suggest that patients who use well
water make their salt solution with bottled water instead.)
More. . .
Copyright © 2014 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.PharmacistsLetter.com ~ www.PrescribersLetter.com ~ www.PharmacyTechniciansLetter.com
(PL Detail-Document #301105: Page 2 of 5)
QUESTION
What are some
commercially available
treatments for oral
mucositis?
ANSWER




What are some common
ingredients of
compounded “magic
mouthwash”? What is the
rationale for these?



How effective is magic
mouthwash?



Continued

An OTC antacid liquid (e.g., Amphojel) or film-forming agent (e.g., Zilactin) can be tried.2
Rx oral protectants (e.g., Episil, Gelclair [alcohol-free], and MuGard-all U.S. only) may be more convenient than
OTC products.2 However, they can cost $100/week or more.5
Commercial kits for compounding “magic mouthwash” are available in the U.S. These include:
o First-Mouthwash BLM (diphenhydramine, lidocaine, aluminum/magnesium hydroxide)
o First-BXN Mouthwash (diphenhydramine, lidocaine, nystatin)
o First-Duke’s Mouthwash (diphenhydramine, hydrocortisone, nystatin)
o First-Mary’s Mouthwash (diphenhydramine, hydrocortisone, nystatin, tetracycline)
Magic mouthwash kits might be easier to e-prescribe and bill for than compounded products. However, kits are
typically about three times more expensive than mixing the mouthwash from scratch using individual ingredients
(approximately $25 to $40 vs $5 to $15), and kits only come in specific combinations and concentrations.6
The logic behind “magic mouthwash” is to combine ingredients with different mechanisms of action.5 There are
numerous magic mouthwash formulations. Most have at least three ingredients. Recipes may contain a
combination of an antibiotic (to reduce the bacterial flora around the lesion), antihistamine (for local anesthetic
effect), antifungal (to stop any fungal growth), steroid (to reduce inflammation), a local anesthetic/pain reliever, or
an antacid (to enhance coating of the ingredients on the mouth).7
Common ingredients of magic mouthwash recipes include viscous lidocaine, diphenhydramine, milk of magnesia,
kaolin with pectin, and aluminum/magnesium hydroxide.2
The most popular magic mouthwash formulation includes viscous lidocaine and diphenhydramine plus
aluminum/magnesium hydroxide to help ingredients coat the mouth.
There is a lack of controlled studies to evaluate the efficacy of the many different magic mouthwash recipes.
Whether one recipe is more effective than another is unknown.8,12
The 2004 guidelines for the treatment of oral mucositis suggest that magic mouthwashes (with various
combinations of viscous lidocaine, benzocaine, milk of magnesia, kaolin-pectin, chlorhexidine, or
diphenhydramine) are no better than normal saline solution in pain relief.9 In addition, a Cochrane review found
magic mouthwash (containing lidocaine, diphenhydramine, and aluminum hydroxide) to be ineffective in
shortening the healing time of oral mucositis related to cancer therapies.10 There is also concern about the
absorption of anesthetics such as lidocaine when used on damaged mucosa.9
Although frequently used as an ingredient of magic mouthwash, nystatin has not been shown to be effective in
treating oral fungal infection associated with mucositis.7 It is also suggested that the high sugar content of nystatin
suspension may feed the fungus.8
Corticosteroids have not been studied adequately to be recommended as an ingredient of magic mouthwash, and
More. . .
Copyright © 2014 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.PharmacistsLetter.com ~ www.PrescribersLetter.com ~ www.PharmacyTechniciansLetter.com
(PL Detail-Document #301105: Page 3 of 5)
QUESTION
ANSWER
continued
How effective is magic
mouthwash?

Where can I find recipes
for magic mouthwash?



What are some tips for
compounding magic
mouthwash?




What are some tips for
billing compounded magic
mouthwash products?


Continued
there’s concern that long-term use may lead to oral candidiasis.
Despite the lack of evidence that magic mouthwashes work in decreasing the pain associated with
chemotherapy/radiation-induced mucositis, canker sores, or other oral pain conditions, many patients and
prescribers continue to use them. There is a need to standardize the ingredients used to compound magic
mouthwash in order to fully evaluate efficacy.
We have a number of different recipes in our PL Chart, Magic Mouthwash Recipes.
Most formulations are used every four to six hours with instructions to hold in the mouth for one to two minutes
then spit out or swallow. (Those with lidocaine should be spit out.)12 Patients should be instructed not to eat or
drink for 30 minutes after use.7
Focal application should be used when possible, instead of widespread topical administration.2
When compounding these mixtures, try to avoid using elixir formulations as the alcohol content can cause
stinging. Consider injectable or bulk powder formulations, crushed tablets, or opened capsules if needed.
In some cases injectable formulations are used in place of elixirs. Some U.S. clinicians have found the new
formulation of Kaopectate (i.e., containing bismuth) to solidify over a short period of time when mixed with other
ingredients. U.S. clinicians should consider this potential problem if utilizing recipes which use Kaopectate in the
place of Maalox. Canadian Kaopectate formulation does not contain bismuth.
The combination of lidocaine and sucralfate in magic mouthwash may not be compatible in some recipes. Some
clinicians report the formation of a thick gel when the two ingredients are mixed.
Prior to dispensing magic mouthwash, pharmacists should verify the formula and patient allergies. Patients should
be counseled regarding the proper use of magic mouthwash (e.g., to shake well before use, hold in mouth for a
minute or two, whether to swallow or not, etc).
Billing for magic mouthwash is not straightforward and varies among different pharmacies. There is no single
NDC number that can be used to bill for magic mouthwash mixed from individual ingredients. In addition, some
of the ingredients used in the magic mouthwash are OTC products, which may not be covered by some insurances.
Some pharmacists are left with the option of billing for a single prescription ingredient used for the compound and
for the full bottle used since billing a partial bottle is not allowed by insurance companies. Some pharmacists have
the patient pay cash. In some cases, the dispensing software allows the pharmacist to enter each ingredient used
and the cost of each ingredient for billing. In other cases, pharmacists may choose to bill each ingredient
separately as separate prescriptions.
The magic mouthwash compounding kits each come with a single unique NDC number accounting for all the
ingredients, which can make billing less complicated in some cases. It may be easier to compound with these kits
More. . .
Copyright © 2014 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.PharmacistsLetter.com ~ www.PrescribersLetter.com ~ www.PharmacyTechniciansLetter.com
(PL Detail-Document #301105: Page 4 of 5)
QUESTION
ANSWER
continued
What are some tips for
billing compounded magic
mouthwash products?

than having to measure and mix each individual ingredient. These compounding kits have also gone through
stability testing and have specified stability duration for an expiration date. Lastly, these mouthwashes have added
flavors and may be better tasting than mouthwashes compounded from scratch. Check insurance coverage before
assembling the kit. Medicare and Medicaid coverage may be spotty because these are compounding kits, not
approved drug products. However, some managed plans may still cover the kits.
Prescribers should specify mouthwash kits by brand name or specify the magic mouthwash formula.
What beyond-use date
should be assigned to
compounded magic
mouthwash products?

Beyond-use dates of these mixtures can vary depending on the ingredients and their individual expiration dates. In
general, per USP standards, if a mixture contains water and is a mucosal liquid, the beyond-use date should not be
longer than 30 days (room temperature).7,11 Oral mixtures containing water should have an expiration not longer
than two weeks (refrigerated).11
How should pain from
oral mucositis be
managed?

Start with topical anesthetics such as topical lidocaine, 0.5% doxepin mouth rinse, or diphenhydramine mouth
rinse.1,2
Keep in mind most magic mouthwash recipes contain a topical anesthetic.
If topical anesthetics don’t provide relief, consider opioids such as an alcohol-free morphine solution to swish and
swallow, transdermal fentanyl, PCA morphine, etc.1,2,5
What treatments for oral
mucositis should actually
be avoided?





Avoid sucralfate or chlorhexidine, because they aren’t likely to help.1,3,4
Also avoid alcohol-based mouth rinses, which can increase pain.12
Avoid using hydrogen peroxide solutions (e.g., 3% hydrogen peroxide diluted 1:1 with water or normal saline) for
more than two days. These may help remove oral debris, but longer periods of use can slow healing.2
Users of this PL Detail-Document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making
clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national
organizations. Information and internet links in this article were current as of the date of publication.
More. . .
Copyright © 2014 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.PharmacistsLetter.com ~ www.PrescribersLetter.com ~ www.PharmacyTechniciansLetter.com
(PL Detail-Document #301105: Page 5 of 5)
Project Leader in preparation of this PL DetailDocument:
Stacy A. Hester, R.Ph., BCPS,
Assistant Editor
References
1.
2.
3.
4.
5.
6.
Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO
clinical practice guidelines for the management of
mucositis secondary to cancer therapy. Cancer
2014;120:1453-61.
NCI.
Oral
mucositis.
http://www.cancer.gov/cancertopics/pdq/supportivec
are/oralcomplications/HealthProfessional/page5.
(Accessed October 8, 2014).
Worthington HV, Clarkson JE, Bryan G, et al.
Interventions for preventing oral mucositis for
patients with cancer receiving treatment (Review).
Cochrane Database Syst Rev 2011;(4):CD000978.
Clarkson JE, Worthington HV, Furness S, et al.
Interventions for treating oral mucositis for patients
with cancer receiving treatment. Cochrane Database
Syst Rev 2010;(4):CD001973.
Negrin RS, Bedard J, Toljanic JA. Oral toxicity
associated with chemotherapy.
Last updated
September 12, 2014. In UpToDate, Basow DS (ed),
UpToDate, Waltham, MA 02013.
Cutis
Pharmaceuticals.
http://www.cutispharma.com. (Accessed October 9,
2014).
7.
Chan A, Ignoffo RJ. Survey of topical oral solutions
for the treatment of chemo-induced oral mucositis. J
Oncol Pharm Pract 2005;11:139-43.
8. Dodd MJ, Dibble SL, Miaskowski C, et al.
Randomized clinical trial of the effectiveness of 3
commonly
used
mouthwashes
to
treat
chemotherapy-induced mucositis. Oral Surg Oral
Med Oral Pathol Oral Radiol Endod 2000;90:39-47.
9. Rubenstein EB, Peterson DE, Schubert M, et al.
Clinical practice guidelines for the prevention and
treatment of cancer therapy-induced oral and
gastrointestinal mucositis.
Cancer 2004;100(9
Suppl):2026-46.
10. Clarkson JE, Worthington HV, Eden OB.
Interventions for treating oral mucositis for patients
with cancer receiving treatment. Cochrane Database
Syst Rev 2007;(2):CD001973.
11. <795> Pharmaceutical Compounding--Nonsterile
Preparations. The United States Pharmacopeia and
The
National
Formulary
(USP-NF).
http://www.usp.org/sites/default/files/usp_pdf/EN/gc7
95.pdf. (Accessed October 9, 2014).
12. Bensinger W, Schubert M, Ang K, et al. NCCN task
force report:
prevention and management of
mucositis in cancer care.
January 2008.
http://www.nccn.org/JNCCN/PDF/mucositis_2008.pd
f. (Accessed October 10, 2014).
Cite this document as follows: PL Detail-Document, Prevention and Treatment of Oral Mucositis. Pharmacist’s
Letter/Prescriber’s Letter. November 2014.
Evidence and Recommendations You Can Trust…
3120 West March Lane, Stockton, CA 95219 ~ TEL (209) 472-2240 ~ FAX (209) 472-2249
Copyright  2014 by Therapeutic Research Center
Subscribers to the Letter can get PL Detail-Documents, like this one,
on any topic covered in any issue by going to www.PharmacistsLetter.com,
www.PrescribersLetter.com, or www.PharmacyTechniciansLetter.com